Cited by 373

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Open access

Knight, Steven D., Adams, Nicholas D., Burgess, Joelle L., Chaudhari, Amita M., Darcy, Michael G., Donatelli, Carla A., Luengo, Juan I., Newlander, Ken A., Parrish, Cynthia A., Ridgers, Lance H., Sarpong, Martha A., Schmidt, Stanley J., Van Aller, Glenn S., Carson, Jeffrey D., Diamond, Melody A., Elkins, Patricia A., Gardiner, Christine M., Garver, Eric, Gilbert, Seth A., Gontarek, Richard R., Jackson, Jeffrey R., Kershner, Kevin L., Luo, Lusong, Raha, Kaushik, Sherk, Christian S., Sung, Chiu-Mei, Sutton, David, Tummino, Peter J., Wegrzyn, Ronald J., Auger, Kurt R., Dhanak, Dashyant·2010·ACS Medicinal Chemistry Letters

DOI 10.1021/ml900028r

Open this paper in CoChat — free account

Abstract

Phosphoinositide 3-kinase α (PI3Kα) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers. The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models. Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1021/ml900028r

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine
Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., & Williams, R. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00089-4 · Cited by 1,197
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells
Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., & Cantley, L. C. (1989) · Cell · doi:10.1016/0092-8674(89)90182-7 · Cited by 908
Self-citation
Signaling by Distinct Classes of Phosphoinositide 3-Kinases
Vanhaesebroeck, B., & Waterfield, M. D. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4701 · Cited by 853
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823
The Identification of 2-(1 H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
Mutation of the PIK3CA oncogene in human cancers
Karakas, B., Bachman, K. E., & Park, B. H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602970 · Cited by 505
Structural insights into phosphoinositide 3-kinase catalysis and signalling
Walker, E. H., Perisic, O., Ried, C., Stephens, L., & Williams, R. L. (1999) · Nature · doi:10.1038/46319 · Cited by 494
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells
Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508988102 · Cited by 324
Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts
Gray, A., Olsson, H., Batty, I. H., Priganica, L., & Downes, C. P. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00607-3 · Cited by 153
Cancer-specific mutations in phosphatidylinositol 3-kinase
Vogt, P. K., Kang, S., Elsliger, M., & Gymnopoulos, M. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.05.005 · Cited by 147
Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Kong, D., & Yamori, T. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803222 · Cited by 115

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Autophagy: The spotlight for cellular stress responses
Ravanan, P., Srikumar, I. F., & Talwar, P. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.08.029 · Cited by 580
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 470
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
mTOR Signaling in Disease
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460

See all 373

Authors: Knight, S. D., Adams, N. D., Burgess, J. L., Chaudhari, A. M., Darcy, M. G., Donatelli, C. A., Luengo, J. I., Newlander, K. A., Parrish, C. A., Ridgers, L. H., Sarpong, M. A., Schmidt, S. J., Van Aller, G. S., Carson, J. D., Diamond, M. A., Elkins, P. A., Gardiner, C. M., Garver, E., Gilbert, S. A., Gontarek, R. R., Jackson, J. R., Kershner, K. L., Luo, L., Raha, K., Sherk, C. S., Sung, C.-M., Sutton, D., Tummino, P. J., Wegrzyn, R. J., Auger, K. R., & Dhanak, D.
Venue: ACS Medicinal Chemistry Letters
Publisher: American Chemical Society (ACS)
Published: 2010-01-19
Volume: 1
Issue: 1
Pages: 39-43
ISSN: 1948-5875 (ISSN-L)
DOI: 10.1021/ml900028r
OpenAlex: W2169303908
Cited by: 373
References: 23
FWCI: 8.51
Type: journal article
Language: en
Open access: green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources